Welcome to our dedicated page for Stimcell Energetics news (Ticker: STME), a resource for investors and traders seeking the latest updates and insights on Stimcell Energetics stock.
StimCell Energetics Inc. (STME) pioneers cellular energy solutions through its clinically validated eBalance® Technology. This news hub provides investors and health innovators with essential updates on therapeutic developments, strategic partnerships, and technological breakthroughs in anti-aging biotech.
Access timely reports on clinical advancements, product commercialization milestones, and collaborative research initiatives. Our curated collection features earnings disclosures, regulatory filings, and analyses of STME's unique approach to cellular optimization through microcurrent applications.
Key updates include progress in home health system development, diagnostic technology enhancements, and market expansion strategies. Stay informed about developments in ATP-focused therapies and non-invasive wellness solutions that position STME at the forefront of preventative health innovation.
Bookmark this page for objective reporting on STME's progress in merging biomedical research with consumer health technology. Regularly updated to reflect the company's evolving role in longevity science and cellular diagnostics.
StimCell Energetics (OTCQB: STME) announced a service agreement, effective December 1, 2025, with St. Boniface Hospital Albrechtsen Research Centre and Principal Investigator Professor Paul Fernyhough to study the eBalance® device.
The approximately three-month project will test how eBalance® microcurrent stimulation affects mitochondrial function in cultured sensory neurons. Experiments will measure oxygen consumption rates (OCR) and related metrics—ATP production, glycolysis, basal and maximal respiration, spare respiratory capacity, coupling efficiency, and proton leak—plus AMPK activity and respiratory protein levels via Western blot. The study uses acute and longer-term stimulation of dissociated adult rat dorsal root ganglia neurons and will deliver a comprehensive report at conclusion.
StimCell Energetics (OTCQB:STME) successfully uplisted to the OTCQB Venture Market, effective October 24, 2025. The company says the uplisting aims to enhance transparency, improve liquidity, and expand visibility with investors by adopting OTCQB reporting and governance standards.
Management highlighted the move as part of a growth strategy to attract new investors and support commercialization of the eBalance® wellness device, while continuing research and market expansion efforts.
StimCell Energetics (OTC PINK:STME) has unveiled progress on its redesigned eBalance® microcurrent therapeutic device. The new version features a smaller form factor and integration with iOS/Android apps, offering personalized health tracking and multiple user profiles. The device is unique in the market as a preventative therapeutic tool designed for lifestyle treatment, requiring 15-minute sessions 2-3 times weekly.
The company has addressed financial obligations by settling $15,000 in outstanding debt through the issuance of 75,000 common shares at $0.20 per share. Additionally, StimCell has engaged Rain Communications Inc. for an eight-month investor relations contract starting March 18, 2025. The agreement includes monthly compensation of 125,000 common shares at $0.20 per share.
StimCell Energetics (OTC PINK:STME) has partnered with ADM Tronics Unlimited (ADMT) to redesign their eBalance® microcurrent device for home use. The new version will be more compact and cost-effective, featuring advanced diagnostic capabilities including real-time cellular energy capacity assessment, treatment tracking, and personalized user profiles.
The eBalance® device utilizes frequency-specific microcurrent technology to stimulate cellular function and promote ATP production, targeting anti-aging, pain relief, and overall vitality. The redesigned consumer unit aims to make this clinical-grade technology more accessible while maintaining its effectiveness in enhancing the body's natural regenerative processes.
StimCell Energetics (OTC PINK:STME) has announced the launch of its social media presence across X, Instagram, and Facebook platforms. The company aims to enhance communication with shareholders, health enthusiasts, and industry contacts. The biotech company, which focuses on cellular energy for anti-aging, longevity, and wellness, positions its eBalance® product as a supplement supporting the five pillars of good health: diet, exercise, sleep, stress avoidance, and hydration.
The company emphasizes the shifting paradigm in the wellness and longevity industry, noting a transition from reactive healthcare to preventative health approaches. CEO David Jeffs expressed excitement about using these platforms to share advancements in health, wellness, anti-aging, and longevity, particularly regarding their eBalance® device.
StimCell Energetics Inc. (OTC PINK:STME), a biotech company focused on cellular energy for anti-aging and wellness, has announced a marketing agreement with Think Ink Marketing. The six-month agreement, which can be terminated with 30-days notice, allocates up to $10,000 monthly for public relations services including online banners and native ads.
Think Ink, established in 1991 in California, will provide digital marketing services including data appending, email marketing, and pay-per-click advertising to increase public awareness of StimCell's products and securities. The company has also completed its rebranding and now trades under the symbol STME.
FAQ
What is the current stock price of Stimcell Energetics (STME)?
What is the market cap of Stimcell Energetics (STME)?
